Literature DB >> 23157944

Outcomes after listing with a requirement for a prospective crossmatch in pediatric heart transplantation.

Brian Feingold1, Seo Young Park, Diane M Comer, Charity G Moore, Steven A Webber, Cindy L Bryce.   

Abstract

BACKGROUND: Allosensitization is associated with inferior waitlist outcomes in pediatric heart transplant candidates, presumably because of the requirement for a negative prospective crossmatch. However, there are no reports of heart transplant candidate outcomes according to prospective crossmatch requirements.
METHODS: We analyzed data on all children listed for isolated heart transplantation from 1995 to 2009 in the USA according to prospective crossmatch requirement (PXMR). Primary objectives were to describe the prevalence of PXMR at and during listing and to compare waitlist and post-transplant survival for patients based on PXMR. Patients with a PXMR during listing include those with a PXMR at the time of listing as well as those who were designated by the listing center as needing a prospective crossmatch at some point after being placed onto the waitlist.
RESULTS: Among 6,343 listed children, 7.7% had a requirement for a prospective crossmatch at the time of listing and 11.8% had a requirement for a prospective crossmatch during listing. After controlling for risk factors associated with inferior survival, PXMR at listing was associated with increased waitlist mortality (HR 1.32, 95% CI 1.10 to 1.56; p = 0.003). Recipients with a PXMR during listing more commonly had a positive DSXM (22.1% vs 10.3%, p < 0.0001), as did recipients who carried a PXMR throughout listing (21.7% vs 11.3%, p = 0.004). However, there was no significant difference in post-transplant survival on the basis of a PXMR during listing (HR 1.04, 95% CI 0.87 to 1.25; p = 0.67). Nearly 30% of recipients with a PXMR during listing had a peak pre-transplant PRA ≤ 10%.
CONCLUSIONS: PXMR increases the likelihood of death while awaiting, but not after, pediatric heart transplantation. Further study is necessary to understand how PXMR is applied, and changes, after listing for pediatric heart transplantation.
Copyright © 2013 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23157944      PMCID: PMC3603363          DOI: 10.1016/j.healun.2012.09.023

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  8 in total

1.  Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database.

Authors:  Joseph W Rossano; David L S Morales; Farhan Zafar; Susan W Denfield; Jeffrey J Kim; John L Jefferies; William J Dreyer
Journal:  J Thorac Cardiovasc Surg       Date:  2010-05-27       Impact factor: 5.209

2.  The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Heart Transplantation Report--2011.

Authors:  Richard Kirk; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Axel O Rahmel; Josef Stehlik; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2011-10       Impact factor: 10.247

3.  Allosensitization and outcomes in pediatric heart transplantation.

Authors:  William T Mahle; Margaret A Tresler; R Erik Edens; Paolo Rusconi; James F George; David C Naftel; Robert E Shaddy
Journal:  J Heart Lung Transplant       Date:  2011-08-06       Impact factor: 10.247

Review 4.  Pediatric cardiac transplantation in children with high panel reactive antibody.

Authors:  Jeffrey P Jacobs; James A Quintessenza; Robert J Boucek; Victor O Morell; Luis M Botero; Vinay Badhwar; Hugh M van Gelder; Alfred Asante-Korang; Jorge McCormack; George R Daicoff
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

5.  Outcomes of children with cardiomyopathy listed for transplant: a multi-institutional study.

Authors:  Anne I Dipchand; David C Naftel; Brian Feingold; Robert Spicer; Delphine Yung; Beth Kaufman; James K Kirklin; Tina Allain-Rooney; Daphne Hsu
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

6.  Survival in allosensitized children after listing for cardiac transplantation.

Authors:  Brian Feingold; Pam Bowman; Adriana Zeevi; Alin L Girnita; Eric S Quivers; Susan A Miller; Steven A Webber
Journal:  J Heart Lung Transplant       Date:  2007-06       Impact factor: 10.247

7.  Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population.

Authors:  Stacey M Pollock-BarZiv; Neal den Hollander; Bo-Yee Ngan; Paul Kantor; Brian McCrindle; Lori J West; Anne I Dipchand
Journal:  Circulation       Date:  2007-09-11       Impact factor: 29.690

8.  Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.

Authors:  D Byron Holt; Douglas M Lublin; Donna L Phelan; Sarah E Boslaugh; Sanjiv K Gandhi; Charles B Huddleston; Jeffrey E Saffitz; Charles E Canter
Journal:  J Heart Lung Transplant       Date:  2007-09       Impact factor: 10.247

  8 in total
  12 in total

1.  Molecular events contributing to successful pediatric cardiac transplantation in HLA sensitized recipients.

Authors:  Monal Sharma; S A Webber; A Zeevi; T Mohanakumar
Journal:  Hum Immunol       Date:  2019-01-30       Impact factor: 2.850

2.  Multiple listing for pediatric heart transplantation in the U.S.A.: analysis of OPTN registry data from 1995 through 2009.

Authors:  Brian Feingold; Seo Y Park; Diane M Comer; Steven A Webber; Cindy L Bryce
Journal:  Pediatr Transplant       Date:  2013-09-30

Review 3.  Current state of pediatric cardiac transplantation.

Authors:  Anne I Dipchand
Journal:  Ann Cardiothorac Surg       Date:  2018-01

4.  Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation.

Authors:  Warren A Zuckerman; Adriana Zeevi; Kristen L Mason; Brian Feingold; Carol Bentlejewski; Linda J Addonizio; Elizabeth D Blume; Charles E Canter; Anne I Dipchand; Daphne T Hsu; Robert E Shaddy; William T Mahle; Anthony J Demetris; David M Briscoe; Thalachallour Mohanakumar; Joseph M Ahearn; David N Iklé; Brian D Armstrong; Yvonne Morrison; Helena Diop; Jonah Odim; Steven A Webber
Journal:  Am J Transplant       Date:  2018-03-23       Impact factor: 8.086

Review 5.  Management of the sensitized pediatric heart transplant patient.

Authors:  Erik L Frandsen; Erin L Albers
Journal:  Transl Pediatr       Date:  2019-10

Review 6.  Donor considerations in pediatric heart transplantation.

Authors:  Nikki Singh; Muhammad Aanish Raees; Farhan Zafar
Journal:  Transl Pediatr       Date:  2019-10

7.  Pediatric and congenital heart transplant: twenty-year experience in a tertiary Brazilian hospital.

Authors:  Leonardo Augusto Miana; Estela Azeka; Luiz Fernando Canêo; Aída Luisa Turquetto; Carla Tanamati; Juliano Gomes Penha; Alexandre Cauduro; Marcelo Biscegli Jatene
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep

8.  Cost-effectiveness of pediatric heart transplantation across a positive crossmatch for high waitlist urgency candidates.

Authors:  B Feingold; S A Webber; C L Bryce; S Y Park; H E Tomko; S C West; S A Hart; W T Mahle; K J Smith
Journal:  Am J Transplant       Date:  2015-06-16       Impact factor: 8.086

9.  Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients.

Authors:  Kevin P Daly; Stephanie F Chandler; Christopher S Almond; Tajinder P Singh; Helen Mah; Edgar Milford; Gregory S Matte; Heather J Bastardi; John E Mayer; Francis Fynn-Thompson; Elizabeth D Blume
Journal:  Pediatr Transplant       Date:  2013-08-06

10.  Association of human leukocyte antigen donor-recipient matching and pediatric heart transplant graft survival.

Authors:  Ryan J Butts; Mark A Scheurer; Andrew M Atz; Omar Moussa; Ali L Burnette; Thomas C Hulsey; Andrew J Savage
Journal:  Circ Heart Fail       Date:  2014-05-15       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.